Cargando…
Promising Schiff bases in antiviral drug design and discovery
Emerging and re-emerging illnesses will probably present a new hazard of infectious diseases and have fostered the urge to research new antiviral agents. Most of the antiviral agents are analogs of nucleosides and only a few are non-nucleoside antiviral agents. There is quite a less percentage of ma...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171175/ https://www.ncbi.nlm.nih.gov/pubmed/37305208 http://dx.doi.org/10.1007/s00044-023-03068-0 |
_version_ | 1785039373425704960 |
---|---|
author | Kaushik, Shikha Paliwal, Sarvesh Kumar Iyer, Malliga R. Patil, Vaishali M. |
author_facet | Kaushik, Shikha Paliwal, Sarvesh Kumar Iyer, Malliga R. Patil, Vaishali M. |
author_sort | Kaushik, Shikha |
collection | PubMed |
description | Emerging and re-emerging illnesses will probably present a new hazard of infectious diseases and have fostered the urge to research new antiviral agents. Most of the antiviral agents are analogs of nucleosides and only a few are non-nucleoside antiviral agents. There is quite a less percentage of marketed/clinically approved non-nucleoside antiviral medications. Schiff bases are organic compounds that possess a well-demonstrated profile against cancer, viruses, fungus, and bacteria, as well as in the management of diabetes, chemotherapy-resistant cases, and malarial infections. Schiff bases resemble aldehydes or ketones with an imine/azomethine group instead of a carbonyl ring. Schiff bases have a broad application profile not only in therapeutics/medicine but also in industrial applications. Researchers have synthesized and screened various Schiff base analogs for their antiviral potential. Some of the important heterocyclic compounds like istatin, thiosemicarbazide, quinazoline, quinoyl acetohydrazide, etc. have been used to derive novel Schiff base analogs. Keeping in view the outbreak of viral pandemics and epidemics, this manuscript compiles a review of Schiff base analogs concerning their antiviral properties and structural-activity relationship analysis. |
format | Online Article Text |
id | pubmed-10171175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-101711752023-05-11 Promising Schiff bases in antiviral drug design and discovery Kaushik, Shikha Paliwal, Sarvesh Kumar Iyer, Malliga R. Patil, Vaishali M. Med Chem Res Review Article Emerging and re-emerging illnesses will probably present a new hazard of infectious diseases and have fostered the urge to research new antiviral agents. Most of the antiviral agents are analogs of nucleosides and only a few are non-nucleoside antiviral agents. There is quite a less percentage of marketed/clinically approved non-nucleoside antiviral medications. Schiff bases are organic compounds that possess a well-demonstrated profile against cancer, viruses, fungus, and bacteria, as well as in the management of diabetes, chemotherapy-resistant cases, and malarial infections. Schiff bases resemble aldehydes or ketones with an imine/azomethine group instead of a carbonyl ring. Schiff bases have a broad application profile not only in therapeutics/medicine but also in industrial applications. Researchers have synthesized and screened various Schiff base analogs for their antiviral potential. Some of the important heterocyclic compounds like istatin, thiosemicarbazide, quinazoline, quinoyl acetohydrazide, etc. have been used to derive novel Schiff base analogs. Keeping in view the outbreak of viral pandemics and epidemics, this manuscript compiles a review of Schiff base analogs concerning their antiviral properties and structural-activity relationship analysis. Springer US 2023-05-10 2023 /pmc/articles/PMC10171175/ /pubmed/37305208 http://dx.doi.org/10.1007/s00044-023-03068-0 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Kaushik, Shikha Paliwal, Sarvesh Kumar Iyer, Malliga R. Patil, Vaishali M. Promising Schiff bases in antiviral drug design and discovery |
title | Promising Schiff bases in antiviral drug design and discovery |
title_full | Promising Schiff bases in antiviral drug design and discovery |
title_fullStr | Promising Schiff bases in antiviral drug design and discovery |
title_full_unstemmed | Promising Schiff bases in antiviral drug design and discovery |
title_short | Promising Schiff bases in antiviral drug design and discovery |
title_sort | promising schiff bases in antiviral drug design and discovery |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171175/ https://www.ncbi.nlm.nih.gov/pubmed/37305208 http://dx.doi.org/10.1007/s00044-023-03068-0 |
work_keys_str_mv | AT kaushikshikha promisingschiffbasesinantiviraldrugdesignanddiscovery AT paliwalsarveshkumar promisingschiffbasesinantiviraldrugdesignanddiscovery AT iyermalligar promisingschiffbasesinantiviraldrugdesignanddiscovery AT patilvaishalim promisingschiffbasesinantiviraldrugdesignanddiscovery |